1887

Abstract

The objectives of this study were to assess the activity of oxytetracycline (OTC), danofloxacin and tulathromycin against subsp. Small Colony, the causative agent of contagious bovine pleuropneumonia, in an dynamic concentration model and to determine the concentration and/or time dependence of such activity. Time–kill assays that simulated elimination of antimicrobials from the body were performed. Initial antimicrobial concentrations corresponded to various multiples of the MIC and cultures were diluted in a stepwise fashion with either drug-free or drug-containing artificial medium to mimic administration by single-release bolus or infusion, respectively. Where appropriate, data were fitted to sigmoidal models. OTC produced no change in mycoplasma titre from the initial inoculum size, regardless of the concentration or means of drug exposure. Both danofloxacin and tulathromycin resulted in a decrease in mycoplasma titre but neither was bactericidal (99.9 % kill) over 12 h. A greater antimycoplasmal effect, defined as the change in log (c.f.u. ml) over 12 h, was achieved when danofloxacin was administered as a single-release bolus, suggesting concentration-dependent activity, whereas the antimycoplasmal effect of tulathromycin was comparable following administration by single-release bolus or infusion, owing to its long half-life.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.045971-0
2013-01-01
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/1/56.html?itemId=/content/journal/jmm/10.1099/jmm.0.045971-0&mimeType=html&fmt=ahah

References

  1. Ayling R. D., Baker S. E., Nicholas R. A. J., Peek M. L., Simon A. J. 2000; Comparison of in vitro activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against Mycoplasma mycoides subspecies mycoides small colony type. Vet Rec 146:243–246 [View Article][PubMed]
    [Google Scholar]
  2. Ayling R. D., Bisgaard-Frantzen S., March J. B., Godinho K., Nicholas R. A. J. 2005; Assessing the in vitro effectiveness of antimicrobials against Mycoplasma mycoides subsp. mycoides small-colony type to reduce contagious bovine pleuropneumonia infection. Antimicrob Agents Chemother 49:5162–5165 [View Article][PubMed]
    [Google Scholar]
  3. Craigmill A. L., Miller G. R., Gehring R., Pierce A. N., Riviere J. E. 2004; Meta-analysis of pharmacokinetic data of veterinary drugs using the food animal residue avoidance databank: oxytetracycline and procaine penicillin G. J Vet Pharmacol Ther 27:343–353 [View Article][PubMed]
    [Google Scholar]
  4. Fischer C. D., Beatty J. K., Zvaigzne C. G., Morck D. W., Lucas M. J., Buret A. G. 2011; Anti-inflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-κB signaling and CXCL8 transcription. Antimicrob Agents Chemother 55:338–348 [View Article][PubMed]
    [Google Scholar]
  5. Giles C. J., Magonigle R. A., Grimshaw W. T. R., Tanner A. C., Risk J. E., Lynch M. J., Rice J. R. 1991; Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J Vet Pharmacol Ther 14:400–410 [View Article][PubMed]
    [Google Scholar]
  6. Gloede J., Scheerans C., Derendorf H., Kloft C. 2010; In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother 65:186–201 [View Article][PubMed]
    [Google Scholar]
  7. Huebschle O. J. B., Ayling R. D., Godinho K., Lukhele O., Tjipura-Zaire G., Rowan T. G., Nicholas R. A. J. 2006; Danofloxacin (Advocin) reduces the spread of contagious bovine pleuropneumonia to healthy in-contact cattle. Res Vet Sci 81:304–309 [View Article][PubMed]
    [Google Scholar]
  8. Jores J., Nkando I., Sterner-Kock A., Haider W., Poole J., Unger H., Muriuki C., Wesonga H., Taracha E. L. 2008; Assessment of in vitro interferon-γ responses from peripheral blood mononuclear cells of cattle infected with Mycoplasma mycoides ssp. mycoides small colony type. Vet Immunol Immunopathol 124:192–197 [View Article][PubMed]
    [Google Scholar]
  9. Kesteman A. S., Ferran A. A., Perrin-Guyomard A., Laurentie M., Sanders P., Toutain P. L., Bousquet-Mélou A. 2009; Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model. Antimicrob Agents Chemother 53:4740–4748 [View Article][PubMed]
    [Google Scholar]
  10. Lees P., AliAbadi F. S, Toutain P. L. 2004; PK-PD modelling: an alternative to dose titration studies for antimicrobial drug dosage selection. J Regul Aff 15:175–180
    [Google Scholar]
  11. Lees P., Concordet D., AliAbadi F. S., Toutain P. L. 2006; Drug selection and optimization of dosage schedules to minimize antimicrobial resistance. In Antimicrobial Resistance in Bacteria of Animal Origin pp. 49–71 Edited by Aarestrup F. M. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  12. Levison M. E. 2004; Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 18:451–465, vii [View Article][PubMed]
    [Google Scholar]
  13. Mariner J. C., McDermott J., Heesterbeek J. A. P., Thomson G., Martin S. W. 2006a; A model of contagious bovine pleuropneumonia transmission dynamics in East Africa. Prev Vet Med 73:55–74 [View Article][PubMed]
    [Google Scholar]
  14. Mariner J. C., McDermott J., Heesterbeek J. A. P., Thomson G., Roeder P. L., Martin S. W. 2006b; A heterogeneous population model for contagious bovine pleuropneumonia transmission and control in pastoral communities of East Africa. Prev Vet Med 73:75–91 [View Article][PubMed]
    [Google Scholar]
  15. Meletiadis J., Al-Saigh R., Velegraki A., Walsh T. J., Roilides E., Zerva L. 2012; Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56:403–410 [View Article][PubMed]
    [Google Scholar]
  16. Mitchell J., McKeever D., McKellar Q. 2011 Investigation of antimicrobial action against Mycoplasma mycoides subsp. mycoides SC. In: Proceedings of the British Pharmacological Society http://www.pA2online.org/abstract/Vol9issue3abst056p.pdf
  17. Nowakowski M. A., Inskeep P. B., Risk J. E., Skogerboe T. L., Benchaoui H. A., Meinert T. R., Sherington J., Sunderland S. J. 2004; Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle. Vet Ther 5:60–74[PubMed]
    [Google Scholar]
  18. Provost A., Perreau P., Breard A., le Goff C., Martel J. L., Cottew G. S. 1987; Contagious bovine pleuropneumonia. Rev Sci Tech Off Int Epiz 6:625–679
    [Google Scholar]
  19. Rempe S., Hayden J. M., Robbins R. A., Hoyt J. C. 2007; Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets 7:232–236 [View Article][PubMed]
    [Google Scholar]
  20. Rweyemamu M. M., Litamoi J., Palya V., Sylla D. 1995; Contagious bovine pleuropneumonia vaccines: the need for improvements. Rev Sci Tech 14:593–601[PubMed]
    [Google Scholar]
  21. Sarasola P., Lees P., AliAbadi F. S., McKellar Q. A., Donachie W., Marr K. A., Sunderland S. J., Rowan T. G. 2002; Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica. Antimicrob Agents Chemother 46:3013–3019 [View Article][PubMed]
    [Google Scholar]
  22. Schaumann R., Goldstein E. J. C., Forberg J., Rodloff A. C. 2005; Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54:749–753 [View Article][PubMed]
    [Google Scholar]
  23. Tambi N. E., Maina W. O., Ndi C. 2006; An estimation of the economic impact of contagious bovine pleuropneumonia in Africa. Rev Sci Tech 25:999–1011[PubMed]
    [Google Scholar]
  24. Yaya A., Wesonga H., Thiaucourt F. 2004 Use of long-acting tetracycline for CBPP: preliminary results. In: FAO-OIE-AU/IBAR-IAEA Consultative Group on Contagious Bovine Pleuropneumonia Third Meeting, 12–14 November 2003, Rome
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.045971-0
Loading
/content/journal/jmm/10.1099/jmm.0.045971-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error